Although this is the first meta-analysis to show a variable effect of PTL based on KRAS mutational status in surgically treated patients, a meta-analysis in medically treated patients with metastatic, unresectable CRC showed that the prognostic value of PTL is restricted to the KRAS wild-type population [25]. The gene discussed is KRAS; the disease is colorectal carcinoma.